TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02365597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: 8 mg orally once daily for 28 days on a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
Study: NCT04152291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethyl-Eicosapentaenoic Acid (E-EPA)
Description: 3,9 grams of EPA is added to participants' normal diet.
Study: NCT04232345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
Study: NCT04657263

Intervention type: OTHER
Intervention: Vaccine coverage assessment
Description: Vaccine coverage assessment
Study: NCT02943798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide plus carboplatin
Description: etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Description: Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
Study: NCT03971253

Intervention type: DRUG
Intervention: Peficitinib
Description: Oral
Study: NCT03725332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Care
Description: Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
Study: NCT04549636

Intervention type: OTHER
Intervention: Six-minute walk test (6MWT)
Description: At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).

Intervention type: OTHER
Intervention: Spirometry
Description: At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.

Intervention type: OTHER
Intervention: Spirometry
Description: At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.

Intervention type: OTHER
Intervention: Spirometry
Description: At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.

Intervention type: OTHER
Intervention: Spirometry
Description: At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.

Intervention type: OTHER
Intervention: Plethysmography & DLCO
Description: At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Study: NCT03109288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemastine fumarate
Description: 8 mg/day (divided into 3 doses of 2, 2, and 4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemastine fumarate
Description: 8 mg/day (divided into 3 doses of 2, 2, and 4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x \>= 7d 534 mg po tid x \>= 7d 801 mg po tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x \>= 7d 534 mg po tid x \>= 7d 801 mg po tid
Study: NCT02941783

Intervention type: DRUG
Intervention: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)
Description: Treatment parameters following the physician's decision based on the summary of product characteristics.
Study: NCT04549636

Intervention type: OTHER
Intervention: Plethysmography & DLCO
Description: At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.

Intervention type: OTHER
Intervention: Plethysmography & DLCO
Description: At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.

Intervention type: OTHER
Intervention: Plethysmography & DLCO
Description: At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.

Intervention type: OTHER
Intervention: Airwave Oscillometry
Description: At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.

Intervention type: OTHER
Intervention: Airwave Oscillometry
Description: At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.

Intervention type: OTHER
Intervention: Airwave Oscillometry
Description: At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.

Intervention type: OTHER
Intervention: Airwave Oscillometry
Description: At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
Study: NCT05135936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyperthermia Group
Description: The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-Group
Description: The number of treatments is equal to the number of treatments in the intervention group.
Study: NCT00884078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally adapted manualized problem solving training
Description: The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
Study: NCT01816932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Visit
Description: The intervention is the location of the insertion visit.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Office visit
Study: NCT02496364

Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Study: NCT00753675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474, Vandetanib
Description: 300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474, Vandetanib
Description: 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ZD6474
Description: Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT04821843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherpay
Description: 40-50Gy/1.8-2.2Gy/20-25f

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Radical esophagectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical esophagectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunotherapy
Description: Anti-PD-1/PD-L1 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Anti-PD-1/PD-L1 Antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU Analog based chemotherpay
Description: W1-5 qW or d1-14, q3W according to physician's preference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Analog based chemotherpay
Description: W1-5 qW or d1-14, q3W according to physician's preference

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimotuzumab
Description: 200-400mg, d1,qW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200-400mg, d1,qW
Study: NCT00617448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure haemorrhoidectomy under local anesthesia
Description: For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
Study: NCT01904500

Intervention type: DRUG
Group type: OTHER
Intervention: Pre-operative cefazolin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative cefazolin
Study: NCT02114697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
Study: NCT01986036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Milk-Protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Milk-Protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Soluble calcium powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Soluble calcium powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Porridge-based breakfast.
Description: Oats and water.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Porridge-based breakfast.
Description: Oats and water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge-based breakfast.
Description: Oats and water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Porridge-based breakfast.
Description: Oats and water.
Study: NCT01521559

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Macular Laser Photocoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Study: NCT02805803

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionary
Description: Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
Study: NCT04491409

Intervention type: OTHER
Intervention: Best Practice
Description: Undergo standard of care

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical charts reviewed
Study: NCT02942966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
Study: NCT02974153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403 (Eptinezumab)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403 (Eptinezumab)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02337465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo kilo-voltage cone beam computed tomography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Ultrasound-Guided Radiation Therapy
Description: Undergo ultrasound-guided radiation therapy
Study: NCT04544371

Intervention type: DEVICE
Intervention: gastric ultrasound
Description: Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark

Intervention type: DEVICE
Intervention: gastric ultrasound
Description: Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark

Intervention type: PROCEDURE
Intervention: nasogastric tube insertion
Description: Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.

Intervention type: PROCEDURE
Intervention: nasogastric tube insertion
Description: Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
Study: NCT05802966

Intervention type: BEHAVIORAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, \& Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).

Intervention type: BEHAVIORAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, \& Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
Study: NCT01065103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFR (Fractional Flow Reserve)
Description: Single FFR measurement in non-culprit vessel
Study: NCT01335477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching BIBF 1120 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF 1120 BID (twice daily)
Study: NCT00002965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa (INF alpha)
Description: Subcutaneous injection Monday through Friday for 8 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa (INF alpha)
Description: Subcutaneous injection Monday through Friday for 8 weeks.
Study: NCT00890019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP
Description: 1. A:Intradermal injection 1x10\^8 vp at day 0~2. A:Intradermal injection 1x10\^9 vp at day 0~3. A:Intradermal injection 1x10\^10 vp at day 0~4. A:Intradermal injection 5x10\^10 vp at day 0~5:Intramuscular injection 1x10\^10 vp at day 0~6A:Intramuscular injection 5x10\^10 vp at day 0~7A: Intramuscular injection 2x10\^11 vp at day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP; MVA ME-TRAP
Description: 1. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~2. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~3. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~4. B: AdCh63 ME-TRAP intradermally at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10\^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)
Study: NCT00682084

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
Study: NCT03401710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin 4000 UI will be administered every other day subcutaneously